Work

Cost-effectiveness analysis of adagrasib with or without cetuximab in the treatment of colorectal cancer patients with mutated KRAS G12C

Year: 2025

Type: article

Source: Expert Review of Pharmacoeconomics & Outcomes Research

DOI: 10.1080/14737167.2025.2521439

Authors: Ruihong Yao, Yao Yao, Xue Teng, Yao Jin, Shangwei Guan, Mei Dong, Tong Liu

Institution: Third Affiliated Hospital of Harbin Medical University

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: Natural Science Foundation of Heilongjiang Province

Award: G1621478527

OpenAlex ID: W4411354692

FWCI: 2.917

Cites: 29

Cited by: 3

Related to: 10